Abstract
Primary CNS tumors, despite many advancements in the field of neurosurgery and radio-oncology, have remained universally lethal. Although, until a few years ago, immunotherapy was not considered one of the treatment options in case of these cancers, recent findings have unraveled the complex genetics, anatomy, and function of the immune compartment residing within the central nervous system (CNS), resha** the immunotherapy paradigm. Understanding the unique aspects of immune activation and regulation within the CNS will be critical in the development of any immune-based brain tumor treatment. This new insight has ramifications for a broad spectrum of tumors that arise in the central nervous system. In this chapter, we review the features of the immune system in the context of CNS, its association with tumor development, and the current standing in immunotherapy of primary CNS cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahmed N et al (2017) HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol 3:1094–1101. https://doi.org/10.1001/jamaoncol.2017.0184
Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM (2011) Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 14:1142–1149. https://doi.org/10.1038/nn.2887
Amankulor NM et al (2017) Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev 31:774–786. https://doi.org/10.1101/gad.294991.116
An Z, Aksoy O, Zheng T, Fan QW, Weiss WA (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561–1575. https://doi.org/10.1038/s41388-017-0045-7
Anderson RC et al (2007) Lack of B7 expression, not human leukocyte antigen expression, facilitates immune evasion by human malignant gliomas. Neurosurgery 60:1129–1136. https://doi.org/10.1227/01.Neu.0000255460.91892.44
Badie B, Schartner J (2001) Role of microglia in glioma biology. Microsc Res Tech 54:106–113. https://doi.org/10.1002/jemt.1125
Badie B, Bartley B, Schartner J (2002) Differential expression of MHC class II and B7 costimulatory molecules by microglia in rodent gliomas. J Neuroimmunol 133:39–45. https://doi.org/10.1016/s0165-5728(02)00350-8
Batich KA et al (2017) Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin Cancer Res 23:1898–1909
Belli F et al (2002) Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20:4169–4180. https://doi.org/10.1200/jco.2002.09.134
Bennett FC et al (2018) A combination of ontogeny and CNS environment establishes microglial identity. Neuron 98:1170–1183.e1178. https://doi.org/10.1016/j.neuron.2018.05.014
Berghoff AS et al (2015) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology 17:1064–1075. https://doi.org/10.1093/neuonc/nou307
Beschorner R et al (2002) CD14 expression by activated parenchymal microglia/macrophages and infiltrating monocytes following human traumatic brain injury. Acta Neuropathol 103:541–549. https://doi.org/10.1007/s00401-001-0503-7
Bloch O et al (2014) Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro-Oncology 16:274–279. https://doi.org/10.1093/neuonc/not203
Bloch O et al (2015) Newly diagnosed glioblastoma patients treated with an autologous heat shock protein peptide vaccine: PD-L1 expression and response to therapy. J Clin Oncol 33:2011. https://doi.org/10.1200/jco.2015.33.15_suppl.2011
Bloch O et al (2017) ATIM-14. ALLIANCE A071101: a phase ii randomized trial comparing the efficacy of heat shock protein peptide complex-96 (HSPPC-96) vaccine given with bevacizumab versus bevacizumab alone in the treatment of surgically resectable recurrent glioblastoma. Neuro-Oncology 19:vi29. https://doi.org/10.1093/neuonc/nox168.110
Bogdahn U et al (2011) Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-Oncology 13:132–142. https://doi.org/10.1093/neuonc/noq142
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016) Toxicity and management in CAR T-cell therapy. Mol Tther Oncolytics 3:16011. https://doi.org/10.1038/mto.2016.11
Bradbury MW, Westrop RJ (1983) Factors influencing exit of substances from cerebrospinal fluid into deep cervical lymph of the rabbit. J Physiol 339:519–534. https://doi.org/10.1113/jphysiol.1983.sp014731
Brooks WH, Netsky MG, Normansell DE, Horwitz DA (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med 136:1631–1647. https://doi.org/10.1084/jem.136.6.1631
Brooks WH, Caldwell HD, Mortara RH (1974) Immune responses in patients with gliomas. Surg Neurol 2:419–423
Brown CE et al (2016) Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375:2561–2569. https://doi.org/10.1056/NEJMoa1610497
Cai J et al (2015) Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors. Oncotarget 6:18105–18115. https://doi.org/10.18632/oncotarget.3906
Carty SA et al (2018) The loss of TET2 promotes CD8(+) T cell memory differentiation. J Immunol 200:82–91. https://doi.org/10.4049/jimmunol.1700559
Chen Z et al (2017) Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Res 77:2266–2278. https://doi.org/10.1158/0008-5472.Can-16-2310
Chheda ZS et al (2018) Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med 215:141–157. https://doi.org/10.1084/jem.20171046
Choi BD et al (2019) CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol 37:1049–1058. https://doi.org/10.1038/s41587-019-0192-1
Chongsathidkiet P et al (2018) Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med 24:1459–1468. https://doi.org/10.1038/s41591-018-0135-2
Cloughesy TF et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25:477–486. https://doi.org/10.1038/s41591-018-0337-7
Cobbs CS et al (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62:3347–3350
Conti A, Gulì C, La Torre D, Tomasello C, Angileri FF, Aguennouz M (2010) Role of inflammation and oxidative stress mediators in gliomas. Cancers (Basel) 2:693–712. https://doi.org/10.3390/cancers2020693
Cserr HF, Knopf PM (1992) Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 13:507–512. https://doi.org/10.1016/0167-5699(92)90027-5
Cull AH, Snetsinger B, Buckstein R, Wells RA, Rauh MJ (2017) Tet2 restrains inflammatory gene expression in macrophages. Exp Hematol 55:56–70.e13. https://doi.org/10.1016/j.exphem.2017.08.001
Davila ML et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra225. https://doi.org/10.1126/scitranslmed.3008226
De Maio A (1999) Heat shock proteins: facts, thoughts, and dreams. Shock (Augusta, Ga) 11:1–12. https://doi.org/10.1097/00024382-199901000-00001
Dong H, Zhu G, Tamada K, Chen L (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5:1365–1369. https://doi.org/10.1038/70932
Dotti G, Gottschalk S, Savoldo B, Brenner MK (2014) Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257:107–126. https://doi.org/10.1111/imr.12131
Duerinck J et al (2021) Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial. J Immunother Cancer 9:e002296. https://doi.org/10.1136/jitc-2020-002296
Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360. https://doi.org/10.1146/annurev.immunol.22.012703.104803
Dunn GP, Fecci PE, Curry WT (2012) Cancer immunoediting in malignant glioma. Neurosurgery 71:201–222. https://doi.org/10.1227/NEU.0b013e31824f840d
Dunwiddie TV (1985) The physiological role of adenosine in the central nervous system. Int Rev Neurobiol 27:63–139. https://doi.org/10.1016/s0074-7742(08)60556-5
El Andaloussi A, Lesniak MS (2006) An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro-Oncology 8:234–243. https://doi.org/10.1215/15228517-2006-006
Engelhardt B, Vajkoczy P, Weller RO (2017) The movers and shapers in immune privilege of the CNS. Nat Immunol 18:123–131. https://doi.org/10.1038/ni.3666
Fecci PE et al (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66:3294–3302. https://doi.org/10.1158/0008-5472.Can-05-3773
Filipazzi P, Huber V, Rivoltini L (2012) Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 61:255–263. https://doi.org/10.1007/s00262-011-1161-9
Finney HM, Akbar AN, Lawson AD (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172:104–113. https://doi.org/10.4049/jimmunol.172.1.104
Fraietta JA et al (2018a) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563–571. https://doi.org/10.1038/s41591-018-0010-1
Fraietta JA et al (2018b) Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558:307–312. https://doi.org/10.1038/s41586-018-0178-z
Frey N, Porter D (2019) Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 25:e123–e127. https://doi.org/10.1016/j.bbmt.2018.12.756
Ginhoux F et al (2010) Fate map** analysis reveals that adult microglia derive from primitive macrophages. Science (New York, NY) 330:841–845. https://doi.org/10.1126/science.1194637
Goldmann J, Kwidzinski E, Brandt C, Mahlo J, Richter D, Bechmann I (2006) T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol 80:797–801. https://doi.org/10.1189/jlb.0306176
Goodman AM et al (2017) Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 16:2598–2608. https://doi.org/10.1158/1535-7163.Mct-17-0386
Graeber MB, Scheithauer BW, Kreutzberg GW (2002) Microglia in brain tumors. Glia 40:252–259. https://doi.org/10.1002/glia.10147
Grever MR (2016) BRAF inhibitor: targeted therapy in hairy cell leukemia. Blood 127:2784–2785. https://doi.org/10.1182/blood-2016-03-704262
Hambardzumyan D, Gutmann DH, Kettenmann H (2016) The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 19:20–27. https://doi.org/10.1038/nn.4185
Harling-Berg CJ, Hallett JJ, Park JT, Knopf PM (2002) Hierarchy of immune responses to antigen in the normal brain. Curr Top Microbiol Immunol 265:1–22. https://doi.org/10.1007/978-3-662-09525-6_1
Hassan A, Mosley J, Singh S, Zinn PO (2017) A comprehensive review of genomics and noncoding RNA in gliomas. Top Magn Reson Imaging 26:3–14. https://doi.org/10.1097/rmr.0000000000000111
Hawkins RA, O’Kane RL, Simpson IA, Viña JR (2006) Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr 136:218s–226s. https://doi.org/10.1093/jn/136.1.218S
Heimberger AB et al (2008) Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas clinical cancer research : an official journal of the American association for. Cancer Res 14:5166–5172. https://doi.org/10.1158/1078-0432.Ccr-08-0320
Hilf N et al (2019) Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565:240–245. https://doi.org/10.1038/s41586-018-0810-y
Ji N, Zhang Y, Liu Y, **e J, Wang Y, Hao S, Gao Z (2018) Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial. JCI Insight 3. https://doi.org/10.1172/jci.insight.99145
Johann PD et al (2016) Atypical Teratoid/Rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell 29:379–393. https://doi.org/10.1016/j.ccell.2016.02.001
Johnson BE et al (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (New York, NY) 343:189–193. https://doi.org/10.1126/science.1239947
Johnson LA et al (2015) Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 7:275ra222. https://doi.org/10.1126/scitranslmed.aaa4963
Keskin DB et al (2019) Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565:234–239. https://doi.org/10.1038/s41586-018-0792-9
Khamis ZI, Al-Akkary N, Hua T, Draughon SA, Li Y, Sang Q (2020) Clinical investigations of immunotherapy for human primary brain tumors. Neuroimmunol Neuroinflamm 2020:1–14
Kim H et al (2015) Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res 25:316–327. https://doi.org/10.1101/gr.180612.114
Komohara Y, Ohnishi K, Kuratsu J, Takeya M (2008) Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 216:15–24. https://doi.org/10.1002/path.2370
Koyama S et al (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7:10501. https://doi.org/10.1038/ncomms10501
Kurtulus S et al (2015) TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest 125:4053–4062. https://doi.org/10.1172/jci81187
Li Q, Barres BA (2018) Microglia and macrophages in brain homeostasis and disease. Nat Rev Immunol 18:225–242. https://doi.org/10.1038/nri.2017.125
Li W, Graeber MB (2012) The molecular profile of microglia under the influence of glioma. Neuro-Oncology 14:958–978. https://doi.org/10.1093/neuonc/nos116
Liau LM et al (2018) First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med 16:142. https://doi.org/10.1186/s12967-018-1507-6
Lim M et al (2020) Updated safety phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM. J Clin Oncol 38:2512–2512. https://doi.org/10.1200/JCO.2020.38.15_suppl.2512
Loke P, Allison JP (2003) PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A 100:5336–5341. https://doi.org/10.1073/pnas.0931259100
Long KB et al (2018) CAR T cell therapy of non-hematopoietic malignancies: detours on the road to clinical success. Front Immunol 9:2740–2740. https://doi.org/10.3389/fimmu.2018.02740
Lowther DE, Hafler DA (2012) Regulatory T cells in the central nervous system. Immunol Rev 248:156–169. https://doi.org/10.1111/j.1600-065X.2012.01130.x
Meimand SE, Pour-Rashidi A, Shahrbabak MM, Mohammadi E, Meimand FE, Rezaei N (2022) The prognostication potential of BRCA genes expression in gliomas: a genetic survival analysis study. World Neurosurg 157:e123–e128. https://doi.org/10.1016/j.wneu.2021.09.107
Merzak A, McCrea S, Koocheckpour S, Pilkington GJ (1994) Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor β1. Br J Cancer 70:199–203. https://doi.org/10.1038/bjc.1994.280
Migliorini D et al (2019) Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Neuro-Oncology 21:923–933. https://doi.org/10.1093/neuonc/noz040
Mohammadi E et al (2021) A global, regional, and national survey on burden and quality of care index (QCI) of brain and other central nervous system cancers; global burden of disease systematic analysis 1990-2017. PLoS One 16:e0247120. https://doi.org/10.1371/journal.pone.0247120
Mount CW et al (2018) Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. Nat Med 24:572–579. https://doi.org/10.1038/s41591-018-0006-x
Mueller S et al (2020) Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. J Clin Invest 130:6325–6337. https://doi.org/10.1172/jci140378
Oji Y et al (2016) Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. Int J Cancer 139:1391–1401. https://doi.org/10.1002/ijc.30182
Okada H et al (2011) Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29:330–336. https://doi.org/10.1200/jco.2010.30.7744
O’Rourke DM et al (2017) A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 9:9. https://doi.org/10.1126/scitranslmed.aaa0984
Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro-Oncology 19:v1–v88. https://doi.org/10.1093/neuonc/nox158
Owens T, Renno T, Taupin V, Krakowski M (1994) Inflammatory cytokines in the brain: does the CNS shape immune responses? Immunol Today 15:566–571. https://doi.org/10.1016/0167-5699(94)90218-6
Pan D et al (2018) A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science (New York, NY) 359:770–775. https://doi.org/10.1126/science.aao1710
Payner T, Leaver HA, Knapp B, Whittle IR, Trifan OC, Miller S, Rizzo MT (2006) Microsomal prostaglandin E synthase-1 regulates human glioma cell growth via prostaglandin E2–dependent activation of type II protein kinase A. Mol Cancer Ther 5:1817–1826
Platten M et al (2021) A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature 592:463–468. https://doi.org/10.1038/s41586-021-03363-z
Prins RM et al (2011) Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17:1603–1615. https://doi.org/10.1158/1078-0432.Ccr-10-2563
Rahman M, Dastmalchi F, Karachi A, Mitchell D (2019) The role of CMV in glioblastoma and implications for immunotherapeutic strategies. Onco Targets Ther 8:e1514921. https://doi.org/10.1080/2162402x.2018.1514921
Rampling R et al (2016) A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. J Cancer Res 22:4776–4785. https://doi.org/10.1158/1078-0432.Ccr-16-0506
Reardon DA et al (2018) Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. J Clin Oncol 36:2006–2006. https://doi.org/10.1200/JCO.2018.36.15_suppl.2006
Reardon DA et al (2020) Effect of Nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol 6:1003–1010. https://doi.org/10.1001/jamaoncol.2020.1024
Rizvi NA et al (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:257–265. https://doi.org/10.1016/s1470-2045(15)70054-9
Rodrigues JC et al (2010) Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro-Oncology 12:351–365. https://doi.org/10.1093/neuonc/nop023
Rosenberg SA, Dudley ME (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 101(Suppl 2):14639–14645. https://doi.org/10.1073/pnas.0405730101
Roszman TL, Brooks WH (1980) Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin Exp Immunol 39:395–402
Sampson JH et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–4729. https://doi.org/10.1200/jco.2010.28.6963
Schalper KA et al (2019) Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med 25:470–476. https://doi.org/10.1038/s41591-018-0339-5
Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B (2005) Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 51:279–285. https://doi.org/10.1002/glia.20201
Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science (New York, NY) 348:69–74. https://doi.org/10.1126/science.aaa4971
Schumacher T et al (2014) A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512:324–327. https://doi.org/10.1038/nature13387
Schuster J et al (2015) A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro-Oncology 17:854–861. https://doi.org/10.1093/neuonc/nou348
Schwartzentruber J et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231. https://doi.org/10.1038/nature10833
Shen J et al (2018) ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med 24:556–562. https://doi.org/10.1038/s41591-018-0012-z
Shu XS et al (2018) The epigenetic modifier PBRM1 restricts the basal activity of the innate immune system by repressing retinoic acid-inducible gene-I-like receptor signalling and is a potential prognostic biomarker for colon cancer. J Pathol 244:36–48. https://doi.org/10.1002/path.4986
Squibb BM (2019) Bristol-Myers Squibb announces phase 3 CheckMate-498 study did not meet primary endpoint of overall survival with opdivo (nivolumab) plus radiation in patients with newly diagnosed MGMT-unmethylated glioblastoma multiforme
Squibb BM (2020) Bristol-Myers Squibb provides update on phase 3 Opdivo (nivolumab) CheckMate-548 trial in patients with newly diagnosed MGMT-methylated glioblastoma multiforme. September 5, 2019
Thaci B, Brown CE, Binello E, Werbaneth K, Sampath P, Sengupta S (2014) Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro Oncol 16(10):1304–1312. https://doi.org/10.1093/neuonc/nou045
Tietz S, Engelhardt B (2015) Brain barriers: crosstalk between complex tight junctions and adherens junctions. J Cell Biol 209:493–506. https://doi.org/10.1083/jcb.201412147
Uyttenhove C et al (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269–1274. https://doi.org/10.1038/nm934
Wainwright DA, Sengupta S, Han Y, Lesniak MS (2011) Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro-Oncology 13:1308–1323. https://doi.org/10.1093/neuonc/nor134
Wainwright DA et al (2012) IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 18:6110–6121. https://doi.org/10.1158/1078-0432.Ccr-12-2130
Wang J et al (2016a) Clonal evolution of glioblastoma under therapy. Nat Genet 48:768–776. https://doi.org/10.1038/ng.3590
Wang PF, Liu N, Song HW, Yao K, Jiang T, Li SW, Yan CX (2016b) IDH-1R132H mutation status in diffuse glioma patients: implications for classification. Oncotarget 7:31393–31400. https://doi.org/10.18632/oncotarget.8918
Weathers S-PS et al (2020) A phase I/II clinical trial of autologous CMV-specific T cells in glioblastoma (GBM) patients to reveal a lack of immune effector function. J Clin Oncol 38:2515–2515. https://doi.org/10.1200/JCO.2020.38.15_suppl.2515
Weller RO, Engelhardt B, Phillips MJ (1996) Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol (Zurich, Switzerland) 6:275–288. https://doi.org/10.1111/j.1750-3639.1996.tb00855.x
Weller M et al (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18:1373–1385. https://doi.org/10.1016/s1470-2045(17)30517-x
Wen PY et al (2019) A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res 25:5799–5807. https://doi.org/10.1158/1078-0432.Ccr-19-0261
Wintterle S et al (2003) Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 63:7462–7467
Woo SR et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72:917–927. https://doi.org/10.1158/0008-5472.Can-11-1620
Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA, Fecci PE (2018) T-cell dysfunction in glioblastoma: applying a new framework. Clin Cancer Res 24:3792–3802. https://doi.org/10.1158/1078-0432.Ccr-18-0047
Yang I, Fang S, Parsa AT (2010a) Heat shock proteins in glioblastomas. Neurosurg Clin N Am 21:111–123. https://doi.org/10.1016/j.nec.2009.09.002
Yang I, Tihan T, Han SJ, Wrensch MR, Wiencke J, Sughrue ME, Parsa AT (2010b) CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci 17:1381–1385. https://doi.org/10.1016/j.jocn.2010.03.031
Zhang Q et al (2015) Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525:389–393. https://doi.org/10.1038/nature15252
Zhang I et al (2016) Characterization of arginase expression in glioma-associated microglia and macrophages. PLoS One 11:e0165118–e0165118. https://doi.org/10.1371/journal.pone.0165118
Zhao J et al (2019) Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med 25:462–469. https://doi.org/10.1038/s41591-019-0349-y
Zhou W et al (2015) Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol 17:170–182. https://doi.org/10.1038/ncb3090
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this entry
Cite this entry
Maroufi, S.F., Mohammadi, E., Namvar, M., Iranmehr, A., Rezaei, N., Hanaei, S. (2023). Immunotherapy for Primary Cancers of Central Nervous System. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_240-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-80962-1_240-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-80962-1
Online ISBN: 978-3-030-80962-1
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences